BackGreenyn Biotechnology , Ltd Overview

Greenyn Biotechnology , Ltd Long Term Debt

Latest long-term debt for 6846.TWO: $1.2B.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$1.21B
↑ 64.85% YoYΔ $476.08M vs prior year quarter

Peer trimmed avg / median

Loading

Greenyn Biotechnology , Ltd Long Term Debt History

Loading

Greenyn Biotechnology , Ltd vs. peers: Long Term Debt Comparison

Loading

Greenyn Biotechnology , Ltd Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Greenyn Biotechnology , Ltd (6846.TWO) FAQ

As of the most recent data (June 2026), 6846.TWO shows a long-term debt of $1.2B. That compares with $730M in the prior-year period — up 64.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 6846.TWO's long-term debt is now $1.2B (was $730M) — a 64.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Greenyn Biotechnology , Ltd is outperforming or lagging.

Tracking 6846.TWO's long-term debt over time shows whether Greenyn Biotechnology , Ltd is scaling, shrinking, or reshaping that part of the business. The current reading is $1.2B That compares with $730M in the prior-year period — up 64.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Greenyn Biotechnology , Ltd's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $1.2B) with ownership activity and broader fundamentals.

Greenyn Biotechnology , Ltd's long-term debt is $1.2B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.